• Home
  • NEW DAY MEDICINE
  • 9 (47) 2022
  • 35 — 9 (47) 2022 — Abdurakhmanov M.M., Khamraev A.N., Radzhabova M.S., MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH CHRONIC HEART FAILURE

35 — 9 (47) 2022 — Abdurakhmanov M.M., Khamraev A.N., Radzhabova M.S., MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH CHRONIC HEART FAILURE

MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH CHRONIC HEART FAILURE

Abdurakhmanov M.M., Bukhara State Medical Institute

Khamraev A.N., Bukhara State Medical Institute

Radzhabova M.S., Bukhara State Medical Institute

Resume

The analysis of changes in the content of C-reactive protein (CRP) and the content of proinflammatory cytokines: tumor necrosis factor a (TNFα), interleukin 1β(IL-1β), interleukin-6 (IL-6) in patients with chronic heart failure with diastolic and mixed systolic and diastolic myocardial dysfunction of the left ventricle was carried out. The content of CRP and proinflammatory cytokines TNFα, IL-1β, IL-6 significantly increases in patients with diastolic dysfunction of the left ventricle of the heart. In patients with CHF on the background of postinfarction cardiosclerosis, with the addition of systolic left ventricular myocardial dysfunction to diastolic, a significant significant increase in CRP, TNFβ, IL-1β, IL-6 was revealed, which can serve as a prognostic marker of the risk of coronary events.

Keywords: C-reactive protein, pro-inflammatory cytokines, tumor necrosis factor а, interleukin 1в, interleukin 6, chronic heart failure

First page

211

Last page

215

For citation: Abdurakhmanov M.M., Khamraev A.N., Radzhabova M.S., MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH CHRONIC HEART FAILURE //New Day in Medicine 9 (47)2022 211-215 https://l.clck.bar/b524d

LIST OF REFERENCES:

  1. Драпкина О.М., Концевая А.В., Кравченко А.Я., Будневский А.В., Токмачев Р.Е., Черник Т.А. Биомаркеры ST2 и интерлейкин 33 в оценке кардиального воспаления, фиброза и прогноза пациентов с хронической сердечной недостаточностью // Российский кардиологический журнал 2021; 26(S3):4530
  2. Кручинкина Е.В., Рябов В.В Иммунный ответ при декомпенсации ишемической сердечной недостаточности. // Российский кардиологический журнал 2018; 1 (153): 72-77.
  3. Провоторов В.М., Будневский А.В., Семенкова Г.Г., Шишкина С.В. Провоспалительные цитокины при сочетании с ишемической болезни сердца и хронической обструктивной болезни легких. // Клиническая Медицина. 2015;93(2):5-9.
  4. Токмачев Р.Е., Будневский А.В., Кравченко А.Я. Роль воспаления в патогенезе хронической сердечной недостаточности. Терапевтический Архив. 2016; 88(9):106-10. doi:10.17116/terarkh2016889106-110.
  5. Dick S.A., Epelman S. Chronic Heart Failure and Inflammation What Do We Really Know? Circulation Research. 2016; 119: 159-76. DOI: 10.1161/CIRCRESAHA.116.308030
  6. Grilo G.A., Shaver P.R., Castro Bra´s L.E. Mechanisms of cardioprotection via modulation of the immune response. // Current Opinion in Pharmacology 2017, 33: 6-11. DOI: 10.1016/j. coph.2017.03.002.
  7. Go A.S., Mozaffarian D., Roger V.L., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. // Circulation. 2014; 129:399-410. doi: 10.1161/01.cir.0000442015.53336.12.
  8. Hedayat M. Proinflammatory cytokines in heart fail¬ure: double-edged swords // Heart Fail. Rev. – 2010. – Vol. 15, №6. – P. 543-562.
  9. Mann D.L. Innate immunity and the failing heart: the cytokine hypothesis revisited. // Circ Res. 2015;116:1254-68. doi:10.1161/CIRCRESAHA.116.302317.
  10. Kosar F. Relationship between cytokines and tumour markers in patients with chronic heart failure // Eur. J. Heart Fail. – 2008. – №3. – P. 270-274.
  11. Savarese G., Lund L.H. Global Public Health Burden of Heart Failure. // Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2.
  12. Tao R., Fan Q., Zhang H., et al. Prognostic Significance of Interleukin-34 (IL-34) in Patients with Chronic Heart Failure with or Without Renal Insufficiency. // J Am Heart Assoc. 2017 Apr 1; 6 (4): e004911. DOI: 10.1161/JAHA.116.004911.
  13. Van Tassell B.W., Buckley L.F., Carbone S., et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). // Clin Cardiol. 2017 Sep; 40 (9): 626-32. DOI: 10.1002/ clc.22719
  14. Wu C.K. Plasma levels of tumor necrosis factor-а and interleukin-6 are associated with diastolic heart failure through down regulation of sarcoplasmic reticulum Ca2+ ATPase // Crit. Care Med. – 2011. – Vol. 39, №5. – P. 984-992.

file

download